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The P2X7 receptor antagonist Brilliant Blue G reduces serum human
interferon-γ in a humanized mouse model of graft-versus-host disease
Abstract
Graft-versus-host disease (GVHD) remains a major problem after allogeneic haematopoietic stem cell
transplantation, a curative therapy for haematological malignancies. Previous studies have demonstrated a role
for the adenosine triphosphate (ATP)-gated P2X7 receptor channel in allogeneic mouse models of GVHD. In
this study, injection of human peripheral blood mononuclear cells (PBMCs) into immunodeficient non-obese
diabetic-severe combined immunodeficiency-interleukin (NOD-SCID-IL)-2Rγnull (NSG) mice established a
humanized mouse model of GVHD. This model was used to study the effect of P2X7 blockade in this disease.
From five weeks post-PBMC injection, humanized mice exhibited clinical signs and histopathology
characteristic of GVHD. The P2X7 antagonist, Brilliant Blue G (BBG), blocked ATP-induced cation uptake
into both murine and human cells in vitro. Injection of BBG (50 mg/kg) into NSG mice did not affect
engraftment of human leucocytes (predominantly T cells), or the clinical score and survival of mice. In
contrast, BBG injection reduced circulating human interferon (IFN)-γ significantly, which was produced by
human CD4+ and CD8+ T cells. BBG also reduced human T cell infiltration and apoptosis in target organs of
GVHD. In conclusion, the P2X7 antagonist BBG reduced circulating IFN-γ in a humanized mouse model of
GVHD supporting a potential role for P2X7 to alter the pathology of this disease in humans.
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Graft-versus-host disease (GVHD) remains a major problem after allogeneic haematopoietic 
stem cell transplantation, a curative therapy for haematological malignancies. Previous 
studies have demonstrated a role for the adenosine triphosphate (ATP)-gated P2X7 receptor 
channel in allogeneic mouse models of GVHD. In this study, injection of human peripheral 
blood mononuclear cells (PBMCs) into immunodeficient NOD-SCID-IL2Rγ
null
 (NSG) mice 
established a humanized mouse model of GVHD. This model was used to study the effect of 
P2X7 blockade in this disease. From five weeks post-PBMC injection, humanized mice 
exhibited clinical signs and histopathology characteristic of GVHD. The P2X7 antagonist, 
Brilliant Blue G (BBG), blocked ATP-induced cation uptake into both murine and human 
cells in vitro. Injection of BBG (50 mg/kg) into NSG mice did not affect engraftment of 
human leukocytes (predominantly T cells), or the clinical score and survival of mice. In 
contrast, BBG injection significantly reduced circulating human interferon (IFN)-γ, which 




 T cells. BBG also reduced human T cell infiltration 
and apoptosis in target organs of GVHD. In conclusion, the P2X7 antagonist BBG reduced 
circulating IFN-γ in a humanized mouse model of GVHD supporting a potential role for 







Allogeneic haematopoietic stem cell transplantation (HSCT) is a current curative therapy for 
a range of haematological malignancies, including leukaemia and lymphoma [1]. A common 
complication following transplantation is the development of graft-versus-host disease 
(GVHD), which arises in approximately half of HSCT recipients worldwide [2]. GVHD is 
mediated by transplanted donor immune cells attacking “foreign” host tissue, resulting in 
inflammatory damage to healthy host tissue. The initial host tissue damage by pre-
conditioning regimes used to treat cancer causes a pro-inflammatory environment, which in 
turn leads to activation of donor CD4
+
 T cells through host antigen presenting cells [3]. CD4
+
 
T cells then release additional pro-inflammatory cytokines including interferon (IFN)-γ and 
interleukin (IL)-17, directly causing damage to tissue, as well as activating cytotoxic CD8
+
 T 
cells which further exacerbate disease [4,5]. Current therapies aim to prevent GVHD by 
preventing these T cell responses through general immunosuppression, leaving a patient 
vulnerable to subsequent infection or relapse, demonstrating a vital need for novel 
therapeutics [6].  
The purinergic system comprises a complex network of extracellular signalling molecules 
and plasma membrane receptors, and is involved in a range of physiological processes 
including inflammation and immunity [7]. Adenosine triphosphate (ATP) is a common 
signalling molecule in this system, acting as both an autocrine activation molecule, and a 
danger associated molecular pattern when released by damaged or dying cells [8]. In these 
contexts, extracellular ATP predominantly mediates its effects through activation of the P2X7 





 and other cations including fluorescent dyes [9]. P2X7 is present on 




the P2X7 receptor can result in a variety of downstream signalling events including cytokine 
release, reactive oxygen species formation and cell proliferation [11].  
Extracellular ATP and P2X7 have emerging roles in GVHD. In allogeneic mouse models, 
extracellular ATP accumulates at sites of inflammatory damage, whilst P2X7 is upregulated 
on dendritic cells (DCs) in lymphoid tissues and livers of mice with severe GVHD [12]. 
Notably, pharmacological blockade or genetic deletion of P2X7 reduces disease severity and 
improves survival in allogeneic mouse models of GVHD [12-14]. Studies investigating the 
role of P2X7 in human GVHD are limited, but it has been shown that P2X7 expression is 
higher in colon biopsies from HSCT patients [12]. Additionally, the presence of a loss-of-
function P2RX7 single nucleotide polymorphism (E496A) in either the donor or recipient 
cells correlates to reduced survival after allogeneic HSCT [15].  
Therefore, the current study aimed to investigate the effect of the P2X7 antagonist, Brilliant 
Blue G (BBG), in a pre-clinical humanized mouse model of GVHD. BBG prevented ATP-
induced dye uptake into splenic DCs from NOD-SCID-IL2Rγ
null
 (NSG) mice and peripheral 
blood T cells from humans. NSG mice engrafted with human (h) peripheral blood 
mononuclear cells (PBMCs) demonstrated increased P2X7 expression in the spleen and small 
intestine. Injection of BBG did not alter the engraftment of human leukocytes or the clinical 
signs of GVHD in these mice. In contrast, injection of BBG caused a significant reduction in 
serum hIFN-γ concentrations, and reduced human T cell infiltration and apoptosis in target 






Antibodies for flow cytometry 
Fluorescein isothiocyanate (FITC) conjugated mouse anti-hCD4 (clone: RPA-T4), mouse 
anti-hCD8 (clone: RPA-T8) and mouse anti-hCD45 (clone: HI30) monoclonal antibodies 
(mAb); R-phycoerythrin (PE) conjugated mouse anti-hCD3 (clone: UCHT1) and mouse 
anti-hCD8 (clone: RPA-T8) mAb; peridinin chlorophyll protein (PerCP-Cy5.5) conjugated 
mouse anti-hCD4 (clone: L200) and rat anti-mCD45 (clone: 30-F11) mAb; allophycocyanin 
(APC) conjugated mouse anti-hCD3 (clone: UCHT1) and mouse anti-hCD19 (clone: HIB19) 
mAb were obtained from BD Pharmingen (San Jose, CA, USA). PE-conjugated hamster anti-
murine (m) CD11c mAb (clone: N418) was from BioLegend (San Diego, CA, USA). 
Cells 
Human multiple myeloma RPMI8226 cells were obtained from the European Collection of 
Cell Cultures (Wiltshire, UK). Murine macrophage RAW264.7 cells were obtained from the 
American Type Culture Collection (Manassas, VA, USA). Cells were maintained in RPMI 
1640 medium containing 2 mM GlutaMAX (Thermo Fisher Scientific, Waltham, MA, USA) 
and 10% heat-inactivated foetal bovine serum (FBS) (Bovogen Biologicals; East Keller, 
Australia) at 37°C/5% CO2. Cell lines were checked every two months for Mycoplasma spp. 
infections, using a MycoAlert
TM
 Mycoplasma detection Kit (Lonza; Basel, Switzerland) as 
per the manufacturer’s instructions. Cells were routinely negative for Mycoplasma spp. 
Mice 
Mouse experiments were approved by the Animal Ethics Committee, University of 
Wollongong (Wollongong, Australia). C57BL/6 mice were obtained from Australian 
BioResources (Moss Vale, Australia). P2X7 knock-out (KO) mice [16], backcrossed onto a 




P2RX7 gene was periodically confirmed as described [16]. Female NSG mice, originally 
obtained from The Jackson Laboratory (Bar Harbor, ME, USA), were bred at the Westmead 
Animal Research Facility (Westmead, Australia). NSG mice were housed in filter top cages 
in Tecniplast (Buggugiate, Italy) isolation cabinets, and provided with autoclaved food and 
water, ad libitum.  
Isolation of human PBMCs  
Experiments with human blood were approved by the Human Ethics Committee, University 
of Wollongong. Blood was collected by venepuncture into VACUETTE® lithium heparin 
tubes (Greiner Bio-One; Frickenhausen, Germany). Whole blood was diluted with an equal 
volume of sterile phosphate buffered saline (PBS) (Thermo Fisher Scientific), underlaid with 
Ficoll-Paque PLUS (GE Healthcare; Uppsala, Sweden) and centrifuged (560 x g for 30 min). 
hPBMCs were collected and washed with two volumes of PBS by centrifugation (430 x g for 
5 min) and resuspended in PBS.  
Humanized mouse model of GVHD 
NSG mice were injected intra-peritoneally (i.p) with 10 x 10
6
 hPBMCs in 100 µL sterile PBS 
(hPBMC group), or with 100 µL sterile PBS alone (control group) (day 0). At 3 weeks post-
hPBMC injection, mice were checked for engraftment by immunophenotyping of tail vein 
blood. Mice were monitored up to week 8 or 10 for signs of GVHD using a scoring system 
(involving a score out of 2, for each of the following five criteria; weight loss, hunching, 
decreased activity, fur ruffling, and skin involvement) giving a total clinical score out of 10. 
Mice were euthanized at 8 or 10 weeks post-injection of hPBMCs, or earlier if exhibiting a 
clinical score of ≥ 8 or a weight loss of ≥ 10%, according to the approved animal ethics 
protocol. For BBG blockade, mice were injected with 10 x 10
6
 hPBMCs as above, and with 




mg/kg) (BBG group) (Sigma-Aldrich; St Louis, MO, USA) on days 0 (1 h post-hPBMC 
injection), 2, 4, 6 and 8.  
Immunophenotyping by flow cytometry 
Tail vein blood (50 µL) was collected into 200 µL of citrate solution (Sigma-Aldrich), diluted 
with PBS and centrifuged (500 x g for 5 min). Spleens from euthanized mice were 
homogenized and filtered through 70 µm nylon filters (Falcon Biosciences, New York, NY, 
USA) and centrifuged (300 x g for 5 min). Blood and spleen cells were incubated with 
ammonium chloride potassium lysis buffer (150 mM NH4Cl, 1 mM KHCO3, 0.1 mM 
Na2CO3, pH 7.3) for 5 min and washed in PBS (300 x g for 5 min). Cells were washed in PBS 
containing 2% FBS (300 x g for 3 min), and incubated for 30 min with fluorochrome 
conjugated mAb, including respective isotype controls. Cells were washed with PBS (300 x g 
for 3 min) and data was collected using a BD Biosciences LSRII Flow Cytometer (using band 
pass filters 515/20 for FITC, 575/26 for PE, 675/40 for PerCP-Cy5.5, and 660/20 for APC). 
The relative percentages of cells were analyzed using FlowJo software v8.7.1 (TreeStar Inc.; 
Ashland, OR, USA) (Fig. S1 and Fig. S2).  
Histological analysis 
Tissues from euthanized mice were incubated overnight in neutral buffered (10%) formalin 
(Sigma-Aldrich). Fixed tissues were removed, coated in paraffin, sectioned (5 µm) and 
stained with haematoxylin and eosin (POCD; Artarmon, Australia). Histological changes 
were assessed using a Leica (Wetzlar, Germany) DMIL inverted light microscope at 4x 
objective and images captured using a Motic (Causeway Bay, Hong Kong) Moticam 2 




Isolation of RNA 
Tissues removed from euthanized mice were stored in RNAlater (Sigma-Aldrich) at -20°C 
until required. RNA was isolated using TRIzol reagent (Thermo Fisher Scientific) as per the 
manufacturer’s instructions. Isolated RNA was immediately converted to complementary 
DNA (cDNA), using the qScript cDNA Synthesis Kit (Quanta Biosciences, Beverly, MA, 
USA) as per the manufacturer’s instructions, and stored at -80°C. cDNA was checked by 
PCR amplification of the house keeping gene glyceraldehyde 3-phosphate dehydrogenase 
(Invitrogen, Carlsbad, CA, USA) for 35 cycles (95°C for 1 min, 55°C for 1 min, and 72°C for 
1 min) and a holding temperature of 4°C. Purity and size of amplicons were confirmed by 2% 
agarose gel electrophoresis.  
Quantitative real-time PCR  
Quantitative real-time PCR (qPCR) reactions were performed using TaqMan Universal 
Master Mix II (Thermo Fisher Scientific) according to the manufacturer’s instructions, with 
primers for FAM-labelled murine glyceraldehyde 3-phosphate dehydrogenase 
(Mm99999915_g1) and mIL-1β (Mm00434228_m1), and VIC-labelled mP2X7 
(Mm01199503_m1), and primers for FAM-labelled human hypoxanthine phosphoribosyl 
transferase 1 (Hs99999909_m1) and hIL-1β (Hs01555410_m1), and VIC-labelled hIFN-γ 
(Hs00989291_m1), hIL-17 (Hs00936345_m1), and hP2X7(B) (AIOIXC2) (Thermo Fisher 
Scientific), as indicated. qPCR cycles consisted of two initial steps of 50°C for 2 min, and 
95°C for 10 min and 40 cycles of 95°C for 15 s, and 60°C for 1 min. qPCR reactions were 
conducted in triplicate, and were performed on a Roche Diagnostics (Indianapolis, IN, USA) 





Cell lysates were prepared and immunoblotting was performed as described [18]. Briefly, cell 
lysates (15 µg protein per lane) were loaded into a Mini-PROTEAN TGXTM Precast Gel 
(Bio-Rad, Hercules, CA, USA) and electrophoresed. Proteins were transferred to a 
nitrocellulose membrane (Bio-Rad) using a Bio-Rad Trans-Blot Turbo Blotting System. 
Membranes were washed with Tris-buffered saline (250 mM NaCl and 50 mM Tris, pH 7.5) 
containing 0.2% Tween-20 (TBST) and blocked overnight at 4°C with blocking solution 
(TBST containing 5% milk powder). Membranes were incubated with rabbit anti-mP2X7 
(extracellular epitope) antibody (Ab) (1:500) (Alomone Labs; Jerusalem, Israel) for 2 h at 
room temperature (RT), washed with TBST and incubated with peroxidase-conjugated goat 
anti-rabbit immunoglobulin G (1:1000) (Rockland Immunochemicals; Limerick, PA, USA) 
for 1 h at RT. Membranes were washed with TBST and incubated with SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and images collected using an 
Amersham Imager600 (GE Healthcare).  
ATP-induced YO-PRO-1
2+
 uptake assay 
P2X7 pore formation was quantified by measuring ATP-induced YO-PRO-1
2+
 uptake as 
previously described [19]. Briefly, cells in NaCl medium (145 mM NaCl, 5 mM KCl, 5 mM 
glucose and 10 mM HEPES, pH 7.4) at 37°C were incubated in the absence or presence of 
BBG for 15 min, and then incubated with 1 µM YO-PRO-1 iodide (Molecular Probes, 
Eugene, OR, USA) in the absence or presence of 1 mM ATP (Sigma-Aldrich) for 10 min. 
Incubations were stopped by addition of ice-cold NaCl medium containing 20 mM MgCl2 
(MgCl2 medium) and centrifugation (300 x g for 3 min). Cells were incubated with PE-
conjugated anti-mCD11c or APC-conjugated anti-hCD3 mAb, respectively where indicated, 
for 15 min and washed with NaCl medium. Data was collected using an LSRII Flow 
Cytometer (band-pass filter 515/20 for YO-PRO-1
2+




FACSDiva software version 8.0. Geometric mean fluorescence intensity of YO-PRO-1
2+
 
uptake was analyzed using FlowJo software (Fig. S3). 
Immunohistochemistry 
Paraffin-embedded formalin fixed tissues were sectioned (5 µm) and mounted on Snowcoat 
slides (Leica) coated with porcine gelatin (Sigma-Aldrich). To identify T cells, tissue sections 
were deparaffinised and heat induced epitope retrieval was performed by incubating in 
sodium citrate buffer (10 mM trisodium citrate dehydrate (Sigma-Aldrich) and 0.05% Tween-
20) for 20 min at 95°C. Before all subsequent steps, tissue sections were washed with Tris-
buffered saline (138 mM NaCl, 2.7 mM KCl and 50 mM Tris, pH 7.5) containing 0.05% 
Tween-20  (TBST2). Tissue sections were blocked with PBS containing 20% goat serum 
(Thermo Fisher Scientific) and 3% bovine serum albumin (BSA) (Amresco, Solon, OH, 
USA) for 30 min at RT, and subsequently incubated with rabbit anti-hCD3 mAb  (clone: 
EP449E) (1:50) (Abcam, Cambridge, UK) in TBST2 containing 1% BSA overnight at 4°C. 
Endogenous peroxidase was quenched by incubating with 3% hydrogen peroxide in PBS 
containing 1% BSA for 20 min at RT. Tissue sections were then incubated with horseradish 
peroxidase-conjugated goat anti-rabbit immunoglobulin G (1:250) (Invitrogen) in TBST 
containing 1% BSA for 15 min at RT. Finally, tissue sections were incubated with 3,3 
diaminobenzidine tetrachloride (Sigma-Aldrich) for 5 min at RT, counterstained with 
haematoxylin and dehydrated. To identify apoptotic cells, an In situ Apoptosis Detection Kit 
(Abcam) was used as per the manufacturer’s instructions. Immunohistochemistry images 
were captured using a Leica DMRB microscope and Leica Application Software version 4.3.  
ELISA 
Blood, collected via cardiac puncture from euthanized mice, was incubated for 1 h at RT and 




and sera stored at -80°C. Serum cytokine concentrations were measured using hIFN-γ, hIL-
17, hIL-4 and mIL-1β Ready-Set-Go! ELISPOT Kits (eBioscience, San Diego, CA, USA) as 
per the manufacturer’s instructions. Absorbance (450 and 570 nm) was measured using a 
SpectraMax Plus 384 (Molecular Devices, Sunnyvale, CA, USA). 
Intracellular staining 
Splenocytes, following ammonium chloride potassium buffer lysis, were incubated for 4 h in 
RPMI 1640 medium containing 2 mM L-glutamine (Thermo Fisher Scientific), 10% FBS, 
1% non-essential amino acids (Thermo Fisher Scientific), 55 µM mercaptoethanol (Thermo 
Fisher Scientific), 100 U/mL penicillin/100 µg/mL streptomycin (Thermo Fisher Scientific), 
50 ng/mL phorbol 12-myristate 13-acetate (Sigma-Aldrich), 1 µg/mL ionomycin (Sigma-
Aldrich), and 1 µg/mL GolgiStop
TM
 (BD Biosciences). Cells were centrifuged (300 x g for 5 
min) and washed once with PBS (300 x g for 5 min). Staining was performed using the BD 
Biosciences Intracellular Stain Kit as per the manufacturer’s instructions, mAb added and 
incubated for 30 min at RT. Cells were washed with PBS and data was collected using an 
LSRII Flow Cytometer (band-pass filter 515/20 for FITC, 575/25 for PE, 675/40 for PerCP-





 cells was analyzed using FlowJo software (Fig. S4). 
Statistical Analysis 
Data is given as mean ± standard error of the mean (SEM). Statistical differences were 
calculated using Student’s t-test for single comparisons or one-way analysis of variance 
(ANOVA) with Tukey’s post-hoc test for multiple comparisons. Weight and clinical score 
were analyzed using a repeated measures two-way ANOVA. Survival was compared using 
the log-rank (Mantel-Cox) test. Correlations between cytokines were assessed using 




Prism 5 for PC (GraphPad Software, La Jolla, CA, USA). P < 0.05 was considered 





NSG mice injected with hPBMCs engraft predominantly human CD3
+
 T cells and 
exhibit clinical signs of GVHD 
NSG mice injected with hPBMCs develop GVHD from 4 weeks [20]. In the current study, 
NSG mice were injected i.p. with 10 x 10
6
 freshly isolated hPBMCs (hPBMC group) or 
saline (control group), and observed for signs of GVHD development for up to 8 weeks. At 3 
weeks post-hPBMC injection, mice were checked for engraftment of human cells. hPBMC-





cells, n = 9), whilst as expected, no human leukocytes were observed in three randomly 
selected control mice (Fig. 1a). In hPBMC-injected mice the majority of hCD45
+
 cells were T 




 cells, n = 9) (Fig. 1b). NSG mice injected with hPBMCs 




) engraftment (data not shown), and the 
remaining human leukocytes were negative for both hCD3 and hCD19 (2.5 ± 0.3%, n = 9) 
(Fig. 1c).  
Analysis of spleens from mice euthanized at end point confirmed the absence of human 
leukocytes in control mice (n = 9) (Fig. 1d). hPBMC-injected mice engrafted large amounts 




 cells, n = 9), whilst as expected, no 
human leukocytes were observed in control mice (n = 9) (Fig. 1d). The majority of human 




 cells, n = 9) (Fig. 1e). No 




) were found in the spleen (data not shown), and the remaining 
cells were negative for both hCD3 and hCD19 (1.7 ± 0.3%, n = 9) (Fig. 1f). Analysis of 
human T cells (hCD3
+
) revealed that hPBMC-injected mice demonstrated a significantly 
higher percentage of hCD4
+
 T cells (69.6 ± 6.6%, n = 9) compared to hCD8
+
 T cells (27.6 ± 




As stated above, mice were observed for signs of GVHD for up to 8 weeks. Weight changes 
were similar between hPBMC-injected and control mice from weeks 1-4, with both groups 
demonstrating weight gain. However, hPBMC-injected mice steadily began to lose weight 
from day 30, while saline-injected control mice maintained a weight of over 110% of their 
starting weight throughout the 8 week observation period (P = 0.4154) (Fig. 1h). Saline-
injected control mice did not show any signs of GVHD, and maintained a clinical score of 0 
over the observation period (n = 9). In contrast, hPBMC-injected mice displayed clinical 
signs of GVHD from day 30, first evident as fur ruffling, followed by hunching, reduced 
activity, weight loss, and/or areas of scaly skin patches. hPBMC-injected mice had a mean 
clinical score of 4.3 ± 1.1 at end point. The clinical scores between the two groups were 
significantly different over 8 weeks (n = 9) (P = 0.0038) (Fig. 1i). hPBMC-injected mice 
succumbed to disease from day 40, with a median survival time (MST) of 54 days, and 
exhibited a 55% mortality rate by end point, compared to 100% survival of control mice (P = 
0.0101) (Fig. 1j).  
 
NSG mice injected with hPBMCs show histological evidence of GVHD and increased 
murine P2X7 expression 
Histological analysis of the target organs; liver, small intestine and skin, revealed that mice 
injected with hPBMCs displayed greater leukocyte infiltration and tissue damage compared 
to tissues from control mice (Fig. 2a). Compared to control mice, hPBMC-injected mice 
demonstrated mildly increased leukocyte infiltration, loss of structural integrity and apoptosis 
of cells in the liver (Fig. 2a), mild damage in the small intestine with increased apoptotic cells 
and rounded villi (Fig. 2a), and lastly mild leukocyte infiltration and epidermal thickening in 




P2X7 expression is up-regulated in host tissues in allogeneic mouse models of GVHD 
[12,14]. Therefore, mP2X7 expression in the spleen, liver and small intestine was analyzed 
by qPCR. mP2X7 expression was increased two-fold in the spleens from hPBMC-injected 
mice (2.6 ± 0.6, n = 7) compared to spleens from control mice (1.2 ± 0.6, n = 4), but this 
difference did not reach statistical significance (P = 0.1656) (Fig. 2b). Hepatic mP2X7 
expression was similar in hPBMC-injected (5.5 ± 0.6, n = 6) and control mice (6.9 ± 1.4, n = 
3) (P = 0.4160) (Fig. 2c). mP2X7 expression was approximately two-fold greater in the small 
intestines from hPBMC-injected mice (16.9 ± 2.7, n = 6) compared to control mice (9.9 ± 6.2, 
n = 4), but this did not reach statistical significance (P = 0.2668) (Fig. 2d). 
 
NSG mice express full-length functional P2X7 receptors 
The data above (Fig. 2b-d) demonstrates that NSG mice express P2X7, but it remained 
unknown if NSG mice express functional P2X7. Immunoblotting using an antibody against 
the extracellular domain of P2X7 demonstrated a major band at 81 kDa, corresponding to 
full-length P2X7 [21] in the positive control RAW264.7 macrophages and in NSG 
splenocytes (n = 2) (Fig. 3a). 
To determine if NSG mice express functional P2X7, RAW264.7 cells or splenic leukocytes 
from mice were incubated in the absence or presence of ATP, and YO-PRO-1
2+
 uptake 
assessed by flow cytometry. ATP induced YO-PRO-1
2+
 uptake into positive control 
RAW264.7 cells (n = 4) and CD11c
+
 splenic DCs from C57BL/6 mice (n = 4), but not 
negative control CD11c
+
 splenic DCs from P2X7 KO mice (n = 3) (Fig. 3b). Notably, ATP 
also induced YO-PRO-1
2+
 uptake into CD11c
+
 splenic DCs from NSG mice (n = 5) (Fig 3b). 
This uptake was 50% lower than that of RAW264.7 macrophages (P < 0.005), but three-fold 
greater than that of C57BL/6 CD11c
+





BBG prevents ATP-induced cation uptake into human and murine leukocytes 
Since its initial use in rodent models of multiple sclerosis [22], spinal cord injury [23] and 
Huntington’s disease [24], BBG has been used in over 40 studies to establish the role of 
P2X7 in various disorders [25] including our group in a murine model of amyotrophic lateral 
sclerosis [26]. To confirm that BBG can block hP2X7 and mP2X7, human RPMI8226 and 
murine RAW264.7 cells, both of which express endogenous P2X7 [27,28], were pre-
incubated with increasing concentrations of BBG and then ATP-induced YO-PRO-1
2+
 uptake 
was assessed. BBG exhibited a concentration-dependent inhibition of ATP-induced YO-
PRO-1
2+
 uptake, with maximal inhibition at 1 µM in both cell types, and half maximal 
inhibitory concentrations (IC50) of 99.0 ± 1.2 nM and 59.7 ± 1.2 nM in RPMI8226 cells and 
RAW264.7 cells, respectively (Fig. 4a). These IC50 values are similar to that known for 
recombinant hP2X7 and mP2X7 [25].  
To confirm that BBG can block P2X7 in primary leukocytes, hPBMCs and NSG splenocytes 
were pre-incubated in the absence or presence of BBG, and then ATP-induced YO-PRO-1
2+
 
uptake was assessed. ATP induced significant YO-PRO-1
2+
 uptake into hCD3
+
 T cells, which 
was reduced by 95% by pre-incubation with BBG (P < 0.0001, n = 3) (Fig. 4b). ATP induced 
significant YO-PRO-1
2+
 uptake into NSG CD11c
+
 splenic DCs, which was reduced 92% by 
pre-incubation with BBG (Fig. 4c) (P < 0.0001, n = 3). Basal uptake of YO-PRO-1
2+
 in the 
absence or presence of BBG was similar for each respective cell subtype (Fig. 4b, c). 
 
BBG does not affect engraftment of human cells or prevent GVHD in NSG mice 
To investigate whether P2X7 blockade can prevent disease in a humanized mouse model of 




was subsequently injected every two days from days 0 to 8. Mice were monitored for weight 
loss and signs of GVHD for up to 10 weeks. To determine if BBG affected engraftment of 
human cells, blood was collected at 3 weeks post-hPBMC injection and cells analyzed by 





 cells, n = 14) compared to saline-injected (vehicle control) mice 




 cells, n = 16) (P = 0.9179) (Fig. 5a). In both groups of mice, 
the majority of hCD45
+
 cells were T cells, which did not differ between BBG-injected mice 









 cells, n = 16) (P = 0.7014) (Fig. 5b). Neither group of mice demonstrated 




) (data not shown). The remaining hCD45
+
 cells were 
negative for both hCD3 and hCD19, and the percentage of these cells did not differ between 
BBG-injected mice (2.7 ± 0.4%, n = 14) and saline-injected mice (2.5 ± 0.4%, n = 16) (P = 
0.8291) (Fig. 5c).  
Analysis of spleens from all mice euthanized at end point demonstrated human leukocytes 
comprised the majority of total murine and human leukocytes. BBG-injected mice engrafted 




 cells, n = 13) compared 




 cells, n = 15) (P = 0.9899) (Fig. 5d). 
The majority of human leukocytes in the spleen were T cells, and both BBG-injected mice 









 cells, n = 15) demonstrated similar percentages of T cells (P = 0.2481) (Fig. 5e). No 




) were found in the spleens (data not shown). The remaining 
hCD45
+
 cells were negative for both hCD3 and hCD19, and percentages of these cells did not 
differ between BBG-injected mice (2.7 ± 0.6%, n = 15) and saline-injected mice (2.7 ± 0.6%, 
n = 15) (P = 0.5325) (Fig. 5f). Analysis of the human T cells (hCD3
+
) revealed that BBG- 
and saline-injected mice contained similar percentages of hCD4
+




vs. 72.7 ± 4.3%, n = 15, respectively, P = 0.3515). BBG- and saline-injected mice also 
contained similar percentages of hCD8
+
 T cells (24.0 ± 3.6%, n = 13 vs 22.3 ± 4.1%, n = 15, 
respectively, P = 0.7583). In both BBG- and saline-injected mice, the percentage of hCD4
+
 T 
cells was significantly higher than hCD8
+
 T cells (P < 0.0001) (Fig. 5g).  
As stated above, mice were observed for signs of GVHD for up to 10 weeks. Both BBG- and 
saline-injected humanized mice began to lose weight from day 30 (P = 0.8450) (Fig. 5h). 
Both BBG- and saline-injected mice began to exhibit signs of mild GVHD at day 35, and 
both BBG- and saline-injected mice, exhibited similar clinical scores at end point (5.3 ± 0.5, 
n = 16 vs. 4.9 ± 0.6, n = 14, respectively). The clinical scores between the two groups were 
not significantly different over 8 weeks (P = 0.8356) (Fig. 5i). Survival was also similar in 
both BBG-injected mice (MST of 64 days, and mortality rate of 57%, n = 16) and saline-
injected mice (MST of 60 days and mortality rate of 62%, n = 14), (P = 0.9874 for mortality 
rate) (Fig. 5j).  
 
BBG reduces histological evidence of GVHD in humanized mice 
BBG- and saline-injected humanized mice demonstrated similar damage to the liver with 
some leukocyte infiltration, apoptosis of cells and fibrosis (Fig. 6a). Both BBG- and saline-
injected humanized mice demonstrated structural damage to the small intestine; however, 
BBG-injected humanized mice exhibited decreased leukocyte infiltration compared to saline-
injected humanized mice (Fig. 6a). BBG-injected humanized mice also exhibited mildly 
decreased leukocyte infiltrates in the dermis, decreased apoptotic cells and reduced basal 
vacuolar change of the skin compared to that of saline-injected humanized mice (Fig. 6a). 
Immunohistochemistry of the target organs, liver, small intestine and skin, was used to 




(indicated by black arrows) were identified in the liver, and to a lesser extent in the small 
intestine and skin (Fig. 6b). T cell infiltration in the liver, small intestine and skin appeared to 
be reduced in BBG-injected mice compared to saline-injected mice (Fig. 6b). To confirm 
tissue damage in the liver, small intestine and skin, these target organs were analyzed for 
evidence of apoptosis (fragmented DNA) by immunohistochemistry. Apoptotic cells 
(indicated by red arrows) were evident in the liver and small intestine, and to a lesser extent 
in the skin (Fig. 6c). Apoptosis in these organs appeared to be reduced in BBG-injected mice 
compared to saline-injected mice (Fig. 6c). 
 
BBG-injected mice demonstrate similar mP2X7 and hP2X7 expression in GVHD target 
organs 
To determine whether injection of BBG altered expression of murine (host) or human (donor) 
P2X7 expression in the spleens and target organs of GVHD, tissues from humanized mice 
were analyzed by qPCR. mP2X7 expression was similar in spleens of BBG-injected mice 
(4.6 ± 1.0, n = 6) and saline-injected mice (5.7 ± 0.5, n = 6) (P = 0.5446) (Fig. 7a). mP2X7 
expression in the liver was reduced by 58% in BBG-injected mice (1.6 ± 0.3, n = 4) 
compared to saline-injected mice (3.9 ± 1.2, n = 5), however this difference did not reach 
statistical significance (P = 0.1619) (Fig. 7b). Conversely, mP2X7 expression was increased 
almost two-fold in the small intestines of BBG-injected mice (2.8 ± 0.7, n = 6) compared to 
saline-injected mice (1.6 ± 0.3, n = 5), but this did not reach statistical significance (P = 
0.1763) (Fig. 7c). hP2X7 expression was decreased by 74% in the spleens of BBG-injected 
mice (3.0 ± 0.9, n = 5) compared to saline-injected mice (11.4 ± 3.5, n = 6) and this 
difference approached statistical significance (P = 0.0595) (Fig. 7d). In contrast, hP2X7 




5, and 7.6 ± 2.9, n = 5, respectively) compared to saline-injected mice (3.7 ± 1.1, n = 4, and 
5.7 ± 1.8, n = 6, respectively) (P = 0.4296 and 0.5642, respectively) (Fig. 7e, 7f). 
 
BBG reduces serum human IFN-γ in humanized mice 
IFN-γ and IL-17 are important pro-inflammatory cytokines implicated in the pathogenesis of 
GVHD [4,5]. To determine if BBG treatment altered the amount of these cytokines, serum 
hIFN-γ and hIL-17 concentrations in humanized mice were assessed by ELISA. hIFN-γ was 
present in the serum of all mice for which samples were available (Fig. 8a). Notably, 
treatment with BBG significantly reduced the amount of serum hIFN-γ in BBG-injected mice 
(10.0 ± 2.4 ng/mL, n = 12), which was 54% lower than that of saline-injected mice (21.8 ± 
2.4 ng/mL, n = 13) (P = 0.0023) (Fig. 8a). In contrast, hIL-17 was only detected in the serum 
from four BBG-injected mice (33%) and two saline-injected mice (15%) for which samples 
were available (Fig. 8b). The amount of hIL-17 in the serum of BBG-injected mice (40.8 ± 
21.1 pg/mL, n = 4) was almost ten-fold greater than that of saline-injected mice (4.4 ± 4.0 
pg/mL, n = 2), however this difference did not reach statistical significance (P = 0.1031) (Fig. 
8b).  
To determine the potential source of hIFN-γ and hIL-17, splenocytes were isolated from 





 T cells produced hIFN-γ and to a lesser extent hIL-17 
(Fig. 8c, 8d). The percentage of hIFN-γ-producing hCD8
+
 T cells was four-fold greater than 
hIFN-γ-producing hCD4
+
 T cells from BBG-injected mice (32.6 ± 7.1% vs 8.1 ± 2.1%, 
respectively, n = 4) and saline-injected mice (39.0 ± 18.9% vs 10.2 ± 7.3%, respectively, n = 
3), but this only reached statistical significance in the BBG-injected group (P = 0.0165) (Fig. 








± 4% vs. 2 ± 1%, n = 4, respectively) was similar to saline-injected mice (2 ± 1% vs. 2 ± 1%, 
n = 3, respectively) (P = 0.5046 and 0.8437, respectively) (Fig. 8d).  
To determine if expression of IFN-γ and IL-17 were altered in the spleens, and target organs 
of GVHD, tissues from humanized mice were analyzed by qPCR. hIFN-γ expression was 1.5-
fold greater in the spleens of BBG-injected mice (9.4 ± 3.9, n = 6) compared to saline-
injected mice (6.4 ± 1.2, n = 6), but this difference did not reach statistical significance (P = 
0.4825) (Fig 8e). hIFN-γ expression was similar in livers of BBG-injected mice (1.4 ± 0.1, n 
= 6) and saline-injected mice (1.6 ± 0.3, n = 6) (P = 0.6549) (Fig. 8f). hIFN-γ expression was 
two-fold greater in the small intestines of BBG-injected mice (2.5 ± 1.1, n = 3) compared to 
saline-injected mice (1.2 ± 0.1, n = 4) but again this difference did not reach statistical 
significance (P = 0.2050) (Fig. 8g). hIL-17 expression in spleens of BBG-injected mice (9.6 
± 6.3, n = 5) was similar to saline-injected mice (13.9 ± 4.0, n = 6) (P = 0.5441) (Fig. 8h). 
hIL-17 was not detected in the livers of either BBG-injected mice (n = 2) or saline-injected 
mice (n = 4) (Fig. 8i). hIL-17 expression was two-fold greater in the small intestines of BBG-
injected mice (6.3 ± 2.2, n = 5) compared to saline-injected mice (2.6 ± 1.3, n = 4), but this 
difference did not reach statistical significance (P = 0.2263) (Fig. 8j). 
BBG does not alter murine or human IL-1β expression in humanized mice 
Activation of P2X7 causes IL-1β maturation and release from antigen presenting cells [29], a 
pro-inflammatory cytokine implicated in the pathogenesis of GVHD [30]. Moreover, P2X7-
mediated IL-1β release is involved in the production of IFN-γ [31] and IL-17 [32]. Given the 
identity of the antigen presenting cells involved in human T cell activation in our humanized 
model of GVHD remains unknown and since mIL-1β can stimulate human cells [33,34], the 
expression of both mIL-1β and hIL-1β in the spleen, liver and small intestine from these mice 




mice (6.3 ± 2.8, n = 3) compared to saline-injected mice (2.0 ± 0.9, n = 5), but this difference 
did not reach statistical significance (P = 0.1183) (Fig. 9a). mIL-1β expression was similar in 
the livers and small intestines of BBG-injected (2.7 ± 1.2, n = 5 and 2.5 ± 0.5, n = 6, 
respectively) and saline-injected mice (2.7 ± 0.7, n = 4 and 1.9 ± 0.6, n = 6, respectively) (P = 
0.9552 and 0.4829, respectively) (Fig. 9b, 9c). In contrast to mIL-1β, hIL-1β expression was 
approximately 50% lower in the spleens of BBG-injected mice (2.2 ± 1.1, n = 5) compared to 
saline-injected mice (5.0 ± 2.1, n = 5), but this difference did not reach statistical significance 
(P = 0.2986) (Fig. 9d). hIL-1β expression was not detected in livers or small intestines from 
either BBG- or saline-injected mice (both n = 5) (data not shown). Therefore, given the broad 
expression of mIL-1β within the humanized mice, mIL-1β in the serum of these mice was 
assessed by ELISA. However contrary to mIL-1β expression in tissues, mIL-1β was not 
detected in the serum from BBG-injected (0.0 ± 0.0, n = 12) or saline-injected mice (0.0 ± 







This study aimed to investigate the effect of the P2X7 antagonist, BBG, in a pre-clinical 
humanized mouse model of GVHD. Injection of BBG into humanized mice did not alter 
human leukocyte engraftment or disease progression, as assessed by weight loss, clinical 
score and survival. However, treatment with BBG significantly reduced serum hIFN-γ and 










 T cells than hIFN-γ hCD4
+
 T cells. However, splenic hCD4
+
 T cells were 
more frequent (three-fold) than hCD8
+
 T cells in humanized mice, and therefore the relative 
contribution of each subset to circulating IFN-γ production needs to be further elucidated. 
Pharmacological blockade or genetic deficiency of P2X7 has also been shown to reduce 
serum IFN-γ in allogeneic mouse models of GVHD [12,13]. Additionally, P2X7 activation of 





 T cells in mice [31]. Combined, these findings support a potential role for P2X7 
in GVHD pathology in humans, possibly through the regulation of T cell activation and 
subsequent IFN-γ production. To this end, IFN-γ plays important roles in the up-regulation of 
CXCR3 and subsequent trafficking of T cells to target tissues in allogeneic mouse models of 









cells are important in the initiation and progression of disease, respectively, in an allogeneic 
mouse model of GVHD [36]. Nevertheless, it remains to be determined if P2X7 functions 
through these mechanisms in allogeneic or humanized mouse models of GVHD. 
The current study also identified the presence of serum hIL-17 in a small proportion of 





 T cells (2-3%) from these mice. Due to the relatively small populations, it 




humanized mouse model of GVHD. However, the mean serum hIL-17 concentration was 10-
fold greater in BBG-injected mice compared to saline-injected mice. These results may 
suggest P2X7 blockade promotes hIL-17 production in humanized mice, which contradicts 
previous in vitro results in which P2X7 activation promoted hIL-17 production in T cells 
[31]. Others have shown that a shift from an IFN-γ-producing to an IL-17-producing T cell 
phenotype exacerbates GVHD in an allogeneic mouse model of GVHD [37]. Similarly, 
increased numbers of IL-17-producing T cells were observed in patients with more severe 
GVHD [38]. Investigating IL-17-producing T cells at time points prior to end point or 
through increased sample sizes may assist in addressing the role of P2X7 blockade in IL-17 
production in humanized mice with GVHD.  
Due to the variation observed in hIL-17 mRNA expression between humanized mice, and the 
role of IL-1β in the differentiation of IL-17-producing T cells [39] including models of P2X7 
activation [32], mIL-1β and hIL-1β was also examined in the current study. mIL-1β, but not 
hIL-1β, mRNA expression was detected in the livers and small intestines of humanized mice, 
with no differences observed between BBG- and saline-treatments. In contrast both mIL-1β 
and hIL-1β mRNA expression was detected in the spleens of humanized mice, with BBG 
treatment resulting in a 3-fold increase in mIL-1β mRNA expression and a 50% decrease in 
hIL-1β mRNA expression. However, there was no correlation between hIL-17 and hIL-1β, or 
between hIL-17 and mIL-1β mRNA expression (results not shown). Due to the inability to 
detect serum mIL-1β in these mice, serum mIL-1β could not be compared with serum hIL-17 
(hIFN-γ). The inability to detect serum mIL-1β was not limited to this cytokine, as serum 
hIL-4 was not detected in initial experiments to establish the humanized mouse model, 
despite detection of serum hIFN-γ in these mice (results not shown). 
As previously mentioned, injection of BBG into humanized mice did not alter disease 




examination revealed that BBG reduced the infiltration of leukocytes into the small intestine 
and skin in this humanized mouse model of GVHD. Moreover, there was also histological 
evidence of reduced tissue damage in these tissues from BBG-injected mice compared to 
saline-injected mice, observations supported by immunohistochemical analysis of T cell 





cells in blood and spleens of humanized mice. Others have reported that humanized NSG 
mice exhibit leukocyte infiltration and tissue damage in the liver, small intestine and skin, 
characteristic of GVHD [40]. T cells are the main mediators of disease in this humanized 
mouse model of GVHD [41,42]. Consistent with these reports, immunohistochemical 
analysis with a human CD3 specific mAb detected T cells in the liver, small intestine and 
skin in humanized mice with GVHD. In support of this observation,hP2X7 mRNA was 
detected in the livers and small intestines of humanized mice using qPCR probes to the 
P2X7B splice variant, which is predominantly expressed in human T cells [43], with P2X7 




 T cells [44].   
Collectively, the above data investigating the effect of the P2X7 antagonist, BBG, in a 
humanized mouse model of GVHD both confirms findings from previous studies using P2X7 
antagonists in allogeneic mouse models of GVHD, and provides additional novel insights. 
Similar to allogeneic mouse models of GVHD [12-14], P2X7 antagonism reduced serum 
IFN-γ, immune infiltrates and tissue damage in humanized mice with GVHD. By contrast, no 
therapeutic benefit (weight loss, clinical score or survival) was observed in humanized mice 
with GVHD, but therapeutic benefits were observed in allogeneic mouse models of GVHD 
[12-14]. Besides obvious laboratory, species and mouse strain differences, a number of other 
notable differences remain between these models of GVHD. First, survival time in these 
allogeneic mouse models [12,13] is at least half that compared to humanized mice. Thus, 




humanized mice. Second, in the allogeneic mouse models, P2X7 antagonists were injected 
daily for the first 10 days [12,13] or twice weekly for 28 days [14] in contrast to five 
injections over the first 8 days in our humanized mouse model. Thus, more frequent or 
extended injection regimes may be required to show therapeutic benefits with BBG in 
humanized mice with GVHD. Third, the two studies that reported improved survival in the 
allogeneic mouse models [12,13] used the P2X7 antagonists, pyridoxal-phopshate-6-
azophenyl-2’,4-disulphonic acid, KN-62 or stavudine, rather than BBG. Thus, testing of 
P2X7 antagonists other than BBG in humanized mice with GVHD may be warranted. 
Although it should be noted that BBG at either 50 or 70 mg/kg (i.p. twice weekly for 28 days) 
prevented weight loss in one allogeneic mouse model of GVHD [14], indicating BBG can 
display some therapeutic benefit in this disease. Finally, in each of the allogeneic mouse 
models, recipient mice were first irradiated [12-14] , which causes ATP release [12]. In 
contrast, the humanized mice in our study were not irradiated, potentially eliminating this 
initial release of ATP, which may subsequently activate P2X7 to promote disease. Thus, the 
therapeutic potential of P2X7 antagonists in irradiated humanized mice with GVHD could be 
investigated. 
Finally, this study showed that NSG mice demonstrate full-length functional P2X7. Firstly, 
qPCR revealed expression of P2RX7 mRNA in the spleens, livers and small intestines of 
NSG mice. Secondly, immunoblotting revealed a major band at 81 kDa, correlating to 
glycosylated, full-length P2X7 [45]. Finally, ATP induced YO-PRO-1
2+
 uptake into splenic 
DCs from NSG mice, a process impaired by BBG, and which was absent in splenic DCs from 
P2X7 KO mice. ATP-induced YO-PRO-1
2+
 uptake into splenic DCs from NSG mice was 
significantly higher than splenic DCs from C57BL/6 mice. This is most likely due to the 
absence and presence of a loss-of-function mutation (P451L) [46] in NSG and C57BL/6 




type at this allele, NSG mice are derived from NOD mice [47], a strain known to encode a 
proline residue at amino acid position 451 [48]. 
In conclusion, the current study demonstrates P2X7 blockade with BBG can significantly 
reduce serum hIFN-γ, and inflammation and tissue damage in a humanized mouse model of 
GVHD. The similar clinical course with skewing to Th17 suggests that clinically P2X7 
blockade may be of additive benefit if combined with strategies that limit Th17, such as IL-6 
receptor blockade [49]. This study suggests a potential benefit for P2X7 blockade, but 
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Fig. 1. Engraftment of human leukocytes and development of GVHD in NOD-SCID-
IL2Rγ
null
 (NSG) mice.  
(a-g) NSG mice were injected intra-peritoneally (i.p.) with either 10 x 10
6
 human (h) 
peripheral blood mononuclear cells (PBMCs) (n = 9) or an equal volume of saline (control) 
(n = 9), and monitored for clinical signs of graft-versus-host disease (GVHD) over 8 weeks. 
(a-g) The percentage of human leukocytes in (a-c) blood at 3 weeks post-hPBMC injection 
and (d-f) spleens at end point were determined by flow cytometry. (a, d) hCD45
+
 leukocytes 




















 T cell subsets are expressed as a percentage of total hCD3
+
 leukocytes. 
Data represents group means ± SEM; symbols represent individual mice; * P < 0.05 
compared to hCD8
+
 T cells. (h-j) NSG mice were monitored for (h) weight loss, (i) clinical 
score and (j) survival. Data represents (h, i) group means ± SEM, or (j) percent survival 





 (NSG) mice injected with human leukocytes develop graft-
versus-host disease (GVHD).  
(a-d) NSG mice injected intra-peritoneally (i.p.) with either human (h) peripheral blood 
mononuclear cells (hPBMCs) or saline (control) (day 0) (from Fig. 1) were monitored for 
clinical signs of graft-versus-host disease (GVHD) over 8 weeks. (a) Tissue sections (liver, 
small intestine and skin) from control (top panel) or hPBMC-injected mice (bottom panel) at 




is representative of two mice per group; bar represents 100 µm. (b-d) The relative expression 
of murine (m) P2X7 in (b) spleen, (c) liver and (d) small intestine from mice at end point was 





 (NSG) mice express full-length functional P2X7. 
(a) Lysates of RAW264.7 (RAW) macrophages and splenocytes from NSG mice were 
examined by immunoblotting using an anti-P2X7 antibody. Image is representative of two 
independent experiments. (b) RAW264.7 cells or splenocytes from C57BL/6, P2X7 KO or 
NSG mice in NaCl medium containing 1 µM YO-PRO-1
2+ 
were incubated in the absence or 
presence of 1 mM adenosine triphosphate (ATP) for 10 min at 37°C. The mean fluorescence 
intensity of YO-PRO-1
2+
 uptake into RAW264.7 cells or CD11c
+
 splenic dendritic cells 
(DCs) was then assessed by flow cytometry. ATP-induced YO-PRO-1
2+
 uptake was 
determined as the difference between YO-PRO-1
2+
 uptake in the presence and absence of 
ATP. Data represents group means ± SEM (n = 3 - 5); symbols represent individual replicates 
(RAW264.7 cells) or mice (splenic CD11c
+
 DCs); ** P < 0.005 and *** P < 0.0001 
compared to C57BL/6. 
 
Fig. 4. Brilliant Blue G (BBG) prevents adenosine triphosphate (ATP)-induced cation 
uptake into human and murine leukocytes.  
(a) Human RPMI8226 and murine RAW264.7 cells, (b) human peripheral blood 
mononuclear cells (PBMCs) or (c) NOD-SCID-IL2Rγ
null
 (NSG) splenocytes in NaCl medium 
were pre-incubated for 15 min at 37°C in the absence or presence of (a) BBG as indicated or 
(b, c) 1 µM BBG. Cells were then incubated with 1 µM YO-PRO-1
2+ 




presence of 1 mM adenosine triphosphate (ATP) for 10 min at 37°C. The mean fluorescence 
intensity of YO-PRO-1
2+
 uptake into (a) RPMI8226 or RAW264.7 cells, (b) hCD3
+
 T cells or 
(b) NSG splenic CD11c
+
 dendritic cells (DCs) was then assessed by flow cytometry. (a) 
ATP-induced YO-PRO-1
2+
 uptake is represented as a percentage of maximal ATP response 
in the absence of BBG. (a-c) Data represents group means ± SEM (n = 3); *** P < 0.0001 
compared to respective basal. 
 
Fig. 5. Brilliant Blue G (BBG) does not affect engraftment of human cells.  
(a-j) NOD-SCID-IL2Rγ
null
 (NSG) mice were injected intra-peritoneally (i.p.) with 10 x 10
6
 
human (h) peripheral blood mononuclear cells (PBMCs), and subsequently with saline 
(control) (n = 14) or saline containing Brilliant Blue G (BBG) (50 mg/kg) (n = 16) every two 
days (from days 0-8), and monitored for clinical signs of graft-versus-host disease (GVHD) 
over 10 weeks. (a-g) The percentage of human leukocytes in (a-c) blood at 3 weeks post-
hPBMC injection and (d-f) spleens at end point were determined by flow cytometry. (a, d) 
hCD45
+













 cells are expressed as a percentage of 
total hCD45
+




 T cell subsets are expressed as a percentage 
of total hCD3
+
 leukocytes. Data represents group means ± SEM; symbols represent 
individual mice; *** P < 0.0001 compared to hCD8
+
 T cells. (h-j) NSG mice were monitored 
for (a) weight loss, (b) clinical score, and (c) survival. Data represents (h, i) group means ± 






Fig. 6. Brilliant Blue G (BBG) does not prevent graft-versus-host disease (GVHD) in 
humanized mice.  
(a-c) NOD-SCID-IL2Rγ
null
 (NSG) mice injected intra-peritoneally (i.p.) with 10 x 10
6
 human 
(h) peripheral blood mononuclear cells (PBMCs) (day 0), and with saline (control) or 50 
mg/kg Brilliant Blue G (BBG) (from Fig. 5) were monitored for clinical signs of GVHD over 
10 weeks. Tissue sections (liver, small intestine, and skin) from hPBMC-injected mice 
injected with saline (control) or BBG at end point were stained with (a) haematoxylin and 
eosin, (b) anti-hCD3 monoclonal antibody with 3,3’-diaminobenzidine tetrachloride detection 
system and haematoxylin, or (c) terminal deoxynucleotidyl transferase deoxyuridine 
triphosphate nick-end labelling with 3,3’-diaminobenzidine tetrachloride detection system 
and methyl green. Images were captured by microscopy with each image representative of (a) 
four, or (b, c) two mice per group; bars represent 100 µm; (b) black arrow heads indicate T 
cells, and (c) red arrow heads indicate apoptotic cells.  
  
 
Fig. 7. Brilliant Blue G (BBG) does not impact expression of mP2X7 or hP2X7 in tissues 
in humanized mice. 
(a-f) NOD-SCID-IL2Rγ
null
 (NSG) mice injected intra-peritoneally (i.p.) with 10 x 10
6
 human 
peripheral blood mononuclear cells (day 0), and with saline (control) or 50 mg/kg Brilliant 
Blue G (BBG) (from Fig. 5) were monitored for clinical signs of GVHD over 10 weeks. The 
relative expression of (a-c) murine (m) P2X7 and (d-f) hP2X7 in (a, d) spleen, (b, e) liver, 
and (c, f) small intestine from mice at end point were examined by qPCR. Data represents 





Fig. 8. Brilliant Blue G (BBG) significantly reduces serum human interferon (IFN)-γ in 
humanized mice.  
(a-j) NOD-SCID-IL2Rγ
null
 (NSG) mice were injected intra-peritoneally (i.p.) with 10 x 10
6
 
human (h) peripheral blood mononuclear cells (PBMCs) (day 0), and with saline (control) or 
50 mg/kg Brilliant Blue G (BBG) (from Fig. 5). Concentrations of serum (a) hIFN-γ, and (b) 
hIL-17 were analyzed by ELISA. Data represents group means ± SEM (saline n = 12, BBG 
n = 13); **P < 0.005 compared to saline-injected mice. (c, d) Splenocytes were incubated in 
complete RPMI 1640 medium containing phorbol 12-myristate 13-acetate and ionomycin for 




 T cells producing intracellular (c) hIFN-γ or (d) 
hIL-17 was determined by flow cytometry. Data represents group means ± SEM (saline n = 
3, BBG = 4); symbols represent individual mice; * P < 0.05 compared to corresponding 
hCD4
+
 T cells. (e-j) The relative expression of (e-g) hIFN-γ and (h-j) hIL-17 in (e, h) spleen, 
(f, i) liver and (g, j) small intestine from mice at end point were examined by qPCR. Data 
represents group means ± SEM (n = 2-6); symbols represent individual mice. ND = not 
detected. 
Fig. 9. Brilliant Blue G (BBG) does not alter relative expression of human or murine IL-
1β in humanized mice.  
(a-d) NOD-SCID-IL2Rγ
null
 (NSG) mice were injected intra-peritoneally (i.p.) with 10 x 10
6
 
human (h) peripheral blood mononuclear cells (PBMCs) (day 0), and with saline (control) or 
50 mg/kg Brilliant Blue G (BBG) (from Fig. 5). The relative expression of (a-c) murine (m) 
interleukin (IL)-1β and (d) hIL-1β in (a, d) spleen, (b) liver and (c) small intestine from mice 
at end point were examined by qPCR. Data represents group means ± SEM (n = 3-6); 






Fig. S1. Flow cytometric gating of leukocytes in blood from humanized mice  
Blood cells from humanized mice were labelled with isotype control or CD-specific 
monoclonal antibodies (mAb). Forward and side scatter was used to identify leukocytes, 























Fig. S2. Flow cytometric gating of leukocytes in spleens from humanized mice  
Splenocytes from humanized mice were labelled with isotype control or CD-specific 
monoclonal antibodies (mAb). Forward and side scatter was used to identify leukocytes, 
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Fig. S3. Flow cytometric analysis of YO-PRO-1
2+
 uptake into human hCD3
+
 T cells and 
CD11c
+
 splenic dendritic cells. 
Human PBMCs and splenocytes from NOD-SCID-IL2Rγ
null
 mice were incubated with YO-
PRO-1
2+
 in the absence (basal) (grey histograms) or presence of adenosine triphosphate 
(ATP) (black histograms), and subsequently labelled with anti-human (h) CD3 or anti-murine 
(m) CD11c monoclonal antibody. Forward and side scatter was used to identify leukocytes, 
which were subsequently used to identify hCD3
+
 T cells or murine CD11c
+
 splenic DCs. YO-
PRO-1
2+










 T cells 
Splenocytes from humanized mice were incubated with phorbol 12-myristate 13-acetate and 
ionomycin, and labelled with isotype control or specific monoclonal antibodies. Forward and 
side scatter was used to identify leukocytes, which were subsequently used to identify human 
CD4
+






), and human hCD8
+







subsets. The percentage of hIFN-γ and hIL-17 was quantified as the difference between 
cytokine specific (black histograms) and isotype control (grey histograms) mAb labelling 
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